SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-520215"
 

Sökning: id:"swepub:oai:DiVA.org:uu-520215" > Were cancer patient...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007084naa a2200733 4500
001oai:DiVA.org:uu-520215
003SwePub
008240112s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:154350797
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5202152 URI
0247 a https://doi.org/10.1016/j.lanepe.2023.1006802 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1543507972 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Johansson, Anna L., Vu Karolinska Institutet,Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.4 aut
2451 0a Were cancer patients worse off than the general population during the COVID-19 pandemic? :b A population-based study from Norway, Denmark and Iceland during the pre-vaccination era
264 1b Elsevier,c 2023
338 a electronic2 rdacarrier
520 a Background In a population-based setting, we investigated the risks of testing positive for SARS-CoV-2 and developing severe COVID-19 outcomes among cancer patients compared with the general population.Methods In nationwide cohorts, we identified all individuals in Norway, Denmark and Iceland who tested positive for SARS-CoV-2 or had a severe COVID-19 outcome (hospitalisation, intensive care, and death) from March until December 2020, using data from national health registries. We estimated standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) comparing cancer patients with the general population.Findings During the first wave of the pandemic, cancer patients in Norway and Denmark had higher risks of testing SARS-CoV-2 positive compared to the general population. Throughout 2020, recently treated cancer patients were more likely to test SARS-CoV-2 positive. In Iceland, cancer patients experienced no increased risk of testing positive. The risk of COVID-19-related hospitalisation was higher among cancer patients diagnosed within one year of hospitalisation (Norway: SIR = 2.43, 95% CI 1.89-3.09; Denmark: 2.23, 1.96-2.54) and within five years (Norway: 1.58, 1.35-1.83; Denmark: 1.54, 1.42-1.66). Risks were higher in recently treated cancer patients and in those diagnosed with haematologic malignancies, colorectal or lung cancer. Risks of COVID-19-related intensive care and death were higher among cancer patients. Interpretation Cancer patients were at increased risk of testing positive for SARS-CoV-2 during the first pandemic wave when testing availability was limited, while relative risks of severe COVID-19 outcomes remained increased in cancer patients throughout 2020. Recent cancer treatment and haematologic malignancy were the strongest risk factors.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng
653 a COVID-19
653 a Coronavirus disease 2019
653 a SARS-CoV-2
653 a Severe acute respiratory syndrome coronavirus 2
653 a Cancer
653 a Hospitalisation
653 a Critical care outcomes
653 a Intensive care
653 a Mortality
653 a Nordic
653 a Denmark
653 a Norway
653 a Iceland
7001 a Skog, Annau Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.4 aut
7001 a Johannesen, Tom Borgeu Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.4 aut
7001 a Myklebust, Tor ageu Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;More & Romsdal Hosp Trust, Dept Res & Innovat, Alesund, Norway.4 aut
7001 a Skovlund, Charlotte Wesselu Danish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.4 aut
7001 a Morch, Lina Steinrudu Danish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.4 aut
7001 a Friis, Sorenu Danish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.4 aut
7001 a Gamborg, Madsu Danish Canc Soc Res Ctr, Danish Canc Soc, Canc Surveillance & Pharmacoepidemiol, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.4 aut
7001 a Kristiansen, Marnar Frioheimu Fac Hlth Sci, Ctr Hlth Sci, Torshavn, Faroe Islands.;Natl Hosp Faroe Isl, Torshavn, Faroe Islands.4 aut
7001 a Pettersson, Davidu Natl Board Hlth & Welf, SE-10630 Stockholm, Sweden.4 aut
7001 a Olafsdottir, Elinborg J.u Iceland Canc Soc, ICS Res & Registrat Ctr, POB 5420, IS-105 Reykjavik, Iceland.4 aut
7001 a Birgisson, Helgiu Iceland Canc Soc, ICS Res & Registrat Ctr, POB 5420, IS-105 Reykjavik, Iceland.4 aut
7001 a Palsson, Runolfuru Landspitali The Natl Univ Hosp Iceland, Saemundargata 2, IS-102 Reykjavik, Iceland.;Univ Iceland, Reykjavik, Iceland.4 aut
7001 a Eythorsson, Eliasu Landspitali The Natl Univ Hosp Iceland, Saemundargata 2, IS-102 Reykjavik, Iceland.4 aut
7001 a Irenaeus, Sandrau Uppsala universitet,Cancerimmunterapi,Akadem Sjukhuset, Reg Canc Ctr Cent Sweden, SE-75185 Uppsala, Sweden.4 aut0 (Swepub:uu)sanir765
7001 a Lambe, Matsu Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.;Akadem Sjukhuset, Reg Canc Ctr Cent Sweden, SE-75185 Uppsala, Sweden.4 aut
7001 a Ursin, Giskeu Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Univ Oslo, Inst Basic Med Sci, Oslo, Norway.;Univ Southern Calif, Dept Prevent Med, Los Angeles, CA USA.4 aut
7102 a Karolinska Institutetb Canc Registry Norway, POB 5313 Majorstuen, N-0304 Oslo, Norway.;Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.4 org
7730 t The Lancet Regional Healthd : Elsevierg 31q 31x 2666-7762
8564 u https://doi.org/10.1016/j.lanepe.2023.100680y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1826870/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-520215
8564 8u https://doi.org/10.1016/j.lanepe.2023.100680
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:154350797

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy